Actavis wins FDA approval for Ropinirole extended-release tablets - Pharmaceutical Business Review
Actavis wins FDA approval for Ropinirole extended-release tabletsPharmaceutical Business ReviewActavis Group, a generic pharmaceuticals company, has gained FDA approval for Ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg.
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended ... - MarketWatch (press release)
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended .
Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip - The Pharma Letter
Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic RequipThe Pharma LetterSeparately, Switzerland headquartered Actavis Group, which is currently the subject of a 4.
NuPathe Announces First Quarter 2012 Financial Results and Operational Highlights - MarketWatch (press release)
NuPathe Announces First Quarter 2012 Financial Results and Operational HighlightsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery.
Safeguard Scientifics Announces First Quarter 2012 Financial ResultsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery.